Michelle Swanson-Mungerson

Dr. Michelle Swanson-Mungerson

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
EPEdith Porter
Edith Porter
EAEyal Amiel
Eyal Amiel
NBNandita Bose
Nandita Bose
ABAndrea Bottaro
Andrea Bottaro
WCWilliam H. Carr
William H. Carr
JJJulie Jameson
Julie Jameson
Identifying the “essential” components of an undergraduate immunology lecture course can be daunting because of the varying postgraduate pathways students take. The American Association of Immunologists Education Committee commissioned an Ad Hoc Committee, representing undergraduate, graduate, and medical institutions as well as the biotechnology community, to develop core curricular recommendations for teaching immunology to undergraduates. In a reiterative process involving the American Association of Immunologists teaching community, 14 key topics were identified and expanded to include foundational concepts, subtopics and examples, and advanced subtopics, providing a flexible list for curriculum development and avenues for higher-level learning. Recommendations for inclusive and antiracist teaching that outline opportunities to meet the needs of diverse student populations were also developed. The consensus recommendations can be used to accommodate various course settings and will bridge undergraduate and graduate teaching and prepare diverse students for subsequent careers in the biomedical field.

1 January 2017 in Virology
Verified
Journal Article
Closed access
RIRyan Incrocci
Ryan Incrocci
LBLevi Barse
Levi Barse
ASAmanda Stone
Amanda Stone
SVSai Vagvala
Sai Vagvala
MMMichael Montesano
Michael Montesano
MSMichelle Swanson-Mungerson
Michelle Swanson-Mungerson

30 June 2024 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AMAlejandro M. Mayer
Alejandro M. Mayer
VMVeronica A. Mayer
Veronica A. Mayer
MSMichelle Swanson-Mungerson
Michelle Swanson-Mungerson
Marsha PierceMarsha Pierce
Marsha Pierce
ARAbimael D. D. Rodriguez
Abimael D. D. Rodriguez
Orazio Taglialatela-ScafatiOrazio Taglialatela-Scafati
Orazio Taglialatela-Scafati
The current 2019–2021 marine pharmacology literature review provides a continuation of previous reviews covering the period 1998 to 2018. Preclinical marine pharmacology research during 2019–2021 was published by researchers in 42 countries and contributed novel mechanism-of-action pharmacology for 171 structurally characterized marine compounds. The peer-reviewed marine natural product pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral mechanism-of-action studies for 49 compounds, 87 compounds with antidiabetic and anti-inflammatory activities that also affected the immune and nervous system, while another group of 51 compounds demonstrated novel miscellaneous mechanisms of action, which upon further investigation, may contribute to several pharmacological classes. Thus, in 2019–2021, a very active preclinical marine natural product pharmacology pipeline provided novel mechanisms of action as well as new lead chemistry for the clinical marine pharmaceutical pipeline targeting the therapy of several disease categories.

1 May 2013 in Journal of General Virology
Verified
Journal Article
Open access
RIRyan Incrocci
Ryan Incrocci
MMMolly McCormack
Molly McCormack
MSMichelle Swanson-Mungerson
Michelle Swanson-Mungerson
Epstein–Barr virus (EBV) latently infected B-cells are the precursors of EBV-associated malignancies. EBV-infection induces the production of pro-survival and anti-inflammatory cytokines that may be important in the transition between latency and malignancy. One EBV protein, LMP2A, can be detected in both latently infected resting B-cells and in EBV-associated malignancies. Therefore, we tested the ability of LMP2A to influence cytokine production using both LMP2A-Tg primary B-cells and LMP2A-expressing B-cell lines. Our data demonstrate that LMP2A does not globally alter B-cell-produced cytokine levels, but specifically targets IL-10. Additional studies using ELISA and real-time-RT-PCR confirm that LMP2A utilizes PI3-kinase to increase IL-10 levels. Finally, the data demonstrate that LMP2A-expressing B-cell lines are more dependent on IL-10 for survival in comparison to LMP2A-negative B-cell lines. These data identify a novel function of LMP2A in the alteration of a cytokine that is important for both tumour survival and anti-tumour responses.

26 July 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
JEJames Elste
James Elste
ASAkash Saini
Akash Saini
RMRafael Mejia-Alvarez
Rafael Mejia-Alvarez
AMArmando Mejía
Armando Mejía
CMCésar Millán-Pacheco
César Millán-Pacheco
VTVaibhav Tiwari
Vaibhav Tiwari
A highly critical event in a virus’s life cycle is successfully entering a given host. This process begins when a viral glycoprotein interacts with a target cell receptor, which provides the molecular basis for target virus–host cell interactions for novel drug discovery. Over the years, extensive research has been carried out in the field of virus–host cell interaction, generating a massive number of genetic and molecular data sources. These datasets are an asset for predicting virus–host interactions at the molecular level using machine learning (ML), a subset of artificial intelligence (AI). In this direction, ML tools are now being applied to recognize patterns in these massive datasets to predict critical interactions between virus and host cells at the protein–protein and protein–sugar levels, as well as to perform transcriptional and translational analysis. On the other end, deep learning (DL) algorithms—a subfield of ML—can extract high-level features from very large datasets to recognize the hidden patterns within genomic sequences and images to develop models for rapid drug discovery predictions that address pathogenic viruses displaying heightened affinity for receptor docking and enhanced cell entry. ML and DL are pivotal forces, driving innovation with their ability to perform analysis of enormous datasets in a highly efficient, cost-effective, accurate, and high-throughput manner. This review focuses on the complexity of virus–host cell interactions at the molecular level in light of the current advances of ML and AI in viral pathogenesis to improve new treatments and prevention strategies.

1 June 2017 in Toxicology Letters
Verified
Journal Article
Closed access
MSMichelle Swanson-Mungerson
Michelle Swanson-Mungerson
RIRyan Incrocci
Ryan Incrocci
VSVijay Subramaniam
Vijay Subramaniam
Philip WilliamsPhilip Williams
Philip Williams
MHMary L. Hall
Mary L. Hall
AMAlejandro M. Mayer
Alejandro M. Mayer